Close Menu

Giulia Kennedy, Jessica Meng

Jan 09, 2018

Veracyte said that it is consolidating its clinical, medical, and R&D functions into one department, which will be headed by Giulia Kennedy, who has served as CSO since the company's founding in 2008. The company also appointed Jessica Meng as vice president of marketing. Meng joins Veracyte from Genentech where she led marketing for Avastin in oncology.

More Like This

Jan 20, 2021

Eleven Therapeutics: Yaniv Erlich

Yaniv Erlich has joined Eleven Therapeutics, a startup he cofounded that has locations in the UK and Israel, as CEO and CSO. He retains his post as CSO of MyHeritage. Previously, he was an associate professor of computer science and computational biology at Columbia University and a core member of the New York Genome Center.

Jan 19, 2021

Circulogene: Stephen Unger

Circulogene has appointed Stephen Unger as its CFO. Unger most recently served as a managing director of equity research at Needham & Company. He has also served as CFO of Quotient, which completed a successful initial public offering in 2014. 

Jan 19, 2021

HTG Molecular Diagnostics: Timothy Johnson, Ann Hanham

HTG Molecular Diagnostics has announced that Timothy Johnson has resigned as executive chairman and as a member of HTG's board of directors. Ann Hanham will remain as the firm's led independent director. 

Jan 19, 2021

National Academy of Sciences: Allon Klein, Aviv Regev

The National Academy of Sciences will award the inaugural James Prize in Science and Technology Integration to Allon Klein and Aviv Regev. Klein is a professor of systems biology at Harvard Medical School and Regev is head of Genentech Research and Early Development. They are receiving the price for their development of massively-parallel single-cell genomics to interrogate gene expression profiles that define distinct cell types, their developmental trajectories, and disease states, using integrated tools from molecular biology, engineering, statistics, and computer science. They will be presented with the $50,000 prize at the academy's 2021 annual meeting.

Jan 19, 2021

Sophia Genetics: Kathy Hibbs

Sophia Genetics has named Kathy Hibbs to its board of directors and to its audit committee. Hibbs, the chief legal and regulatory officer at 23andMe, has been chosen for several boards in recent years, including those of Decipher Biosciences and Cadex GenomicsPrior to joining 23andMe, Hibbs served as senior VP and general counsel at Genomic Health.

Jan 19, 2021

Foundation Medicine: Cindy Perettie

Foundation Medicine, a Roche subsidiary, announced Cindy Perettie would be transitioning to Roche Diagnostics to lead the molecular lab solutions business, effective April 6. Perettie has been the CEO of Foundation Medicine since 2019 and previously served as senior VP with product strategy responsibility for the global oncology portfolio at Roche and Genentech. She also led global portfolio management for IVAX Pharmaceuticals and was the president of global development innovations at the Sarah Cannon Research Insitute in Nashville. In addition, she was previously the director of global program management at Élan Corporation in the United Kingdom. 

Brian Alexander, Foundation's chief medical officer and senior VP, will be the interim CEO for the company. 

Jan 15, 2021

Broad Institute: Eric Lander, Todd Golub

Eric Lander, founding director of the Broad Institute of the Massachusetts Institute of Technology and Harvard, has been named White House science advisor to President-elect Joseph Biden. He will specifically be nominated as director of the Office of Science and Technology Policy and serve as Presidential Science Advisor. The President-elect is designating the Presidential Science Advisor as a member of the Cabinet for the first time in history. Lander was a principal leader of the Human Genome Project, and during the Obama Administration he served as external co-chair of the President's Council of Advisors on Science and Technology.

Lander will step down from his roles at Broad, Harvard, and MIT and take an unpaid, academic leave of absence.

The Broad Institute's board has appointed Todd Golub, current chief scientific officer at the institute, as director. Golub is a founder and core member of the institute, and serves on its executive leadership team. He is also the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute and professor of pediatrics at Harvard Medical School. Golub joined the Dana-Farber and Harvard faculty in 1997, and served as a key scientific leader of the Whitehead Institute/MIT Center for Genome Research, the precursor organization of the Broad Institute. He has also been Howard Hughes Medical Institute investigator, and has served as chair of numerous scientific advisory boards, including St. Jude Children's Research Hospital and the National Cancer Institute's scientific advisory board.

Jan 15, 2021

Agilent Technologies: Allison Ballmer

Agilent Technologies has named Allison Ballmer as senior vice president of strategy and corporate development, reporting to President and CEO Mike McMullen.

Ballmer joined Agilent in May 2018 as vice president of business development and strategy for the company's Diagnostics and Genomics business. Prior to that, she worked for more than a decade at Roche. She is currently lead director of the board of directors at Mission Bio.

Jan 15, 2021

Exact Sciences: Andrew Slavitt

In a filing with the US Securities and Exchange Commission, Exact Sciences said that Andrew Slavitt submitted his resignation as a member of the company's board on Jan. 11 after having been been appointed by President-elect Joseph Biden as a White House Senior Advisor for COVID Response. 

Jan 14, 2021

Congenica Patient Advocacy and Engagement Advisory Board

Congenica has created a patient advocacy and engagement advocacy board and named Alastair Kent, former executive director of Genetic Alliance UK, as chair. Other members of the new board are:

  • Cor Oosterwijk, executive director of VSOP, the national patient alliance for rare and genetic diseases in the Netherlands;
  • Nicola Bedlington, former secretary general of and current special advisor to the European Patients' Forum; 
  • Lynsey Chediak, the World Economic Forum's project lead on precision medicine and rare diseases;
  • Luke Rosen, cofounder of rare disease advocacy group KIF1A.org; and
  • Malisa Rust, associate director of patient engagement at PTC Therapeutics.
Jan 14, 2021

LevitasBio: Paul Steinberg and Joseph Walthers

LevitasBio, a Stanford University spinout, has appointed Paul Steinberg as chief commercial officer and Joseph Walthers as VP of finance.

Steinberg will lead LevitasBio's commercial roadmap and strategy and manage commercial functions at the firm. He was most recently VP of worldwide sales at NanoString Technologies and has held leadership roles in commercialization and business development at Fluidigm and Thermo Fisher Scientific, respectively. He holds a master's degree in analytical chemistry from the University of Miami.

Walthers will be responsible for financial planning, budgeting, accounting, risk management, and internal controls activities. He has over 20 years experience at life science and biotech companies including Twist Bioscience, Natera, and Rainin Instrument. He is a licensed CPA in California.

Jan 14, 2021

Sema4: William Oh

Sema4 has appointed William Oh to the position of chief medical science officer, where he will drive strategy, scientific collaborations, clinical development, and adoption of the firm's technology.

Oh comes to Sema4 from Mount Sinai Health System, where he was chief of hematology and medical oncology and the deputy director of the Tisch Cancer Institute at the Icahn School of Medicine. He will continue to see patients at Mount Sinai.

Oh holds an MD from the New York University School of Medicine.

Jan 13, 2021

C2i Genomics: Mark Oldroyd, Ravi Kandasamy, Alex Parker

C2i Genomics has appointed Mark Oldroyd as its chief business officer, Ravi Kandasamy as VP of research and development, and Alex Parker as a member of the firm's board of directors. 

Oldroyd previously served as senior VP at Tempus. Prior to Tempus, he was a senior director at Foundation Medicine.

Kandasamy most recently served as director of genomics at Bristol-Myers Squibb. In addition, he has previously served as manager of research and development in precision medicine at GlaxoSmithKline.

Parker currently serves as senior VP for clinical product strategy at Thrive Earlier Detection. Prior to Thrive, he spent more than seven years in leadership positions at Foundation Medicine. 

Jan 13, 2021

Nanoview Biosciences: David Hanlon

Nanoview has appointed David Hanlon as its VP of strategic collaborations. Hanlon most recently served as VP of strategic communications at Quanterix. He has also held leadership roles at several life sciences and diagnostic firms, including Hologic. 

Jan 08, 2021

Gen InCode: Bill Rhodes

Gen InCode, a privately owned UK-based company specializing in cardiovascular disease genetic risk assessment, has appointed Bill Rhodes as non-executive chairman. Rhodes has previously served as worldwide president of Becton Dickinson's Biosciences business and was BD's corporate executive officer for strategy and corporate development. Rhodes also currently serves as chairman at OpGen, Omega Diagnostics Group, and CytoSmart Technologies. He was formerly chairman of the Curetis supervisory board until that company's merger with OpGen.

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.